Tag: Intravitreal injection

Globally, it's estimated that 1.3 billion people live with some form of vision impairment [1.3.9]. The answer to **which administration route is given into the eye** depends entirely on the target tissue and the specific ocular condition being treated, ranging from simple eye drops to direct injections.

Diabetic macular edema (DME) is a leading cause of vision loss among working-age adults with diabetes, affecting millions worldwide by damaging blood vessels and causing fluid leakage in the macula. The primary treatment to prevent vision loss and, in many cases, improve sight for this condition is through targeted eye injections.

According to clinical trial data for diabetic macular edema (DME), a significant percentage of patients receiving repeated OZURDEX injections experience cataract development and elevated intraocular pressure. The potential problems with OZURDEX are significant and require careful consideration by both patients and their ophthalmologists.

Approximately 28% of patients receiving Ozurdex experience increased eye pressure, a major consideration for aftercare. This guide details **what is the aftercare of Ozurdex injections?** to ensure a smooth recovery, manage common symptoms, and recognize potential complications.

Cimerli (ranibizumab-eqrn), a medication for various retinal conditions, is typically given as a once-monthly treatment, but the precise dosing schedule is tailored to the specific eye disease being treated. As a biosimilar interchangeable with Lucentis, Cimerli offers consistent and effective treatment based on its approved indications.

Initially approved by the FDA in 2004, Macugen (pegaptanib) was the first anti-VEGF therapy to treat wet age-related macular degeneration (AMD), and its administration was a groundbreaking medical procedure for preserving vision. This article details how is Macugen administered through a series of carefully executed intravitreal injections and explains the patient care required during treatment.